Korsana Biosciences lists on Nasdaq after $380m raise

The Waltham-based neurodegenerative disease biotech completed its merger with Cyclerion and a $380m private placement, beginning Nasdaq trading under "KRSA" on 9

The Biotech Times Editorial Team By The Biotech Times Editorial Team AI level 2 of 5
AI level 2 of 5: drafted by our AI editorial assistant from the company's announcement; fact-checked, edited and signed off by Mark Walker, Editorial Director. What the levels mean
A tall, modern skyscraper with reflective blue glass facades and shifting block designs stands against a bright, partly cloudy sky, with blurred buildings in the distant background.

Korsana Biosciences began trading on the Nasdaq Capital Market on 9 September 2026 under the ticker "KRSA", following the completion of its merger with Cyclerion Therapeutics and a $380 million private placement that closed immediately beforehand.

The financing round was led by Fairmount and Venrock Healthcare Capital Partners, with a broad syndicate of co-investors including General Atlantic, Forbion, Wellington Management, RA Capital Management, RTW Investments, Sanofi Ventures, and J.P. Morgan Life Sciences Private Capital, among others. Together with existing cash, Korsana says the combined company holds approximately $475 million in pro-forma cash and cash equivalents, a position the company expects to fund operations into 2029.

The lead programme

Korsana's clinical focus centres on KRSA-028, a next-generation shuttled antibody targeting amyloid beta for Alzheimer's disease. The candidate employs the company's proprietary THETA (Therapeutic Targeting) platform, developed in partnership with Paragon Therapeutics, which combines transferrin receptor (TfR1) engineering and Fc optimisation with the aim of improving brain penetration, safety, and dosing convenience relative to earlier CNS shuttle approaches.

Phase 1 healthy volunteer data are expected in mid-2027, with interim proof-of-concept data assessing amyloid plaque clearance in Alzheimer's patients anticipated by year-end 2027 or the first quarter of 2028. The company has not yet filed an IND, and no clinical safety or efficacy data are available at this stage.

Jonathan Violin, Ph.D., Korsana's president and chief executive, said the company is "well positioned to execute on our long-term vision" of reducing the burden of neurodegenerative diseases, pointing to what he described as an exceptional team and a pipeline of differentiated candidates.

Market context

The anti-amyloid space has drawn intense scrutiny following the approval of lecanemab (Leqembi) and donanemab in the US, and ongoing debates around clinical benefit versus ARIA risk have shaped how investors and regulators view new entrants. KRSA-028's differentiated pitch rests on the THETA shuttle platform, which Korsana positions as capable of achieving higher brain drug concentrations than first-generation transferrin receptor approaches, potentially addressing the dose-limiting brain-oedema signals seen with intravenous anti-amyloid antibodies.

The competitive field also includes several earlier-stage shuttle-antibody programmes from academic spin-outs and emerging biotechs, and the clinical bar is rising as post-approval real-world data on approved agents accumulates. Korsana will need Phase 1 safety data that compares favourably with this backdrop to attract continued investor confidence ahead of its 2027 readouts.

The $475 million cash position is a robust starting point for a pre-clinical-stage Alzheimer's company, and the calibre of the syndicate suggests institutional confidence in the platform. Alzheimer's drug development, however, remains one of the highest-attrition areas in all of biopharmaceuticals, and amyloid-targeting strategies continue to generate both scientific and commercial debate. Investors will be watching the mid-2027 healthy volunteer safety readout as the first real test of KRSA-028's differentiated profile.

Sector

Topic

Geography